FOSUN PHARMA (02196) announced that on September 1, 2026, it repurchased 264,000 shares for a total consideration of HK$4.278 million, at a price range of HK$16.07 to HK$16.28 per share.
The repurchase reflects the company's ongoing capital management strategy amid market conditions.